Shortcomings of the study include the small number of patients with each tumor type, making it difficult to evaluate the antitumor activity of PF-06671008, as well as the lack of a priori determination of P-cadherin levels in patients’ tumors. The gene discussed is CDH3; the disease is neoplasm.